Head to Head Survey: Positron (POSC) versus Its Competitors

Positron (OTCMKTS:POSC) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Positron to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Positron and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	270	803	2019	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,351.31%. Given Positron’s competitors higher possible upside, analysts clearly believe Positron has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Positron and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-12.13
Positron Competitors	$1.00 billion	$85.30 million	5.52

Positron’s competitors have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

44.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 14.7% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Positron and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-331.31%	-92.24%	-30.04%

Volatility & Risk

Positron has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 17.00, indicating that their average stock price is 1,600% more volatile than the S&P 500.

Summary

Positron competitors beat Positron on 7 of the 10 factors compared.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.